When targeted in glioblastoma cells, ACDase inhibition with LV vector-delivered shRNA or carmofur, an inhibitor of ACDase that has been used as an antineoplastic drug since the early 1980s, caused a decrease in AKT signaling, affecting migration of glioblastoma cells [12,140]. This evidence concerns the gene AKT1 and glioblastoma.